PULSE 5-31-26 Tile-based radiation therapy

Executive summary

This report covers the following key findings:

1. Despite the ROADS trial showing a 1.3% vs. 15.4% one-year recurrence rate and median overall survival more than doubling (42.5 vs. 17.6 months), only 38.9% of respondents labeled the treatment a 'major breakthrough' while 50.3% hedged with 'need more research.' This gap between clinical evidence and public perception represents a significant communication challenge for adoption. The treatment's efficacy profile is unambiguous in the trial data, yet the majority of the public remains in a cautious holding pattern rather than embracing the results.

2. Survey respondents lean toward rejecting implanted foreign objects outright (mean score of -0.38 on a -1 to +1 scale), and free-response data show that concerns about having radioactive material in the brain are widespread. However, the dominant concern pattern skews toward requiring concrete safety data rather than assuming unsafety regardless of evidence, suggesting that transparent communication of technical specifications — such as Cs-131's 9.69-day half-life and minimal radiation penetration — could meaningfully shift acceptance. This implies the barrier is informational rather than purely psychological.

3. When asked what would matter most in choosing a brain cancer treatment, 43.4% of respondents prioritized longest possible survival time — the single metric where TBRT most dramatically outperforms standard care. This alignment between patient values and the treatment's headline result suggests that survival-focused messaging will resonate with the largest patient segment. However, 27.1% prioritize lowest risk of side effects and 24.1% prefer treatments proven over many years, meaning safety and track-record messaging must accompany survival claims to reach the full audience.

4. Free-response data on clinical trial trust reveal that 'somewhat trust' is the modal position, and respondents holding this view are more likely to rate the TBRT study as a major breakthrough — indicating that moderate trust is a gateway to enthusiasm rather than a ceiling. External evidence confirms that while two-thirds of the public worry about clinical trial side effects and 66% distrust unproven treatments, nine-in-ten support expanding access to trials, reflecting an underlying openness that targeted communication can activate. The implication is that trust-building messaging should focus on the Phase 3 rigor and FDA-cleared status of GammaTile rather than trying to overcome deep skepticism.

5. Real-world data show that approximately 20% of patients never complete planned postoperative SRT, and delays beyond four weeks are associated with local recurrence rates jumping from 2.3% to 14.5% or higher. TBRT patients completed cranial radiation in a median of one day versus 32 days for SRT, directly eliminating the logistical window during which residual tumor cells proliferate. This compliance advantage is a clinically and operationally compelling argument for TBRT that complements the survival data and addresses a documented failure mode of the current standard of care.

6. Between 70,000 and 400,000 new brain metastasis cases are diagnosed annually in the United States, affecting 10–40% of patients with solid tumors. Lung cancer, melanoma, and breast cancer account for the highest incidence, with melanoma and lung cancer SBMs showing increasing annual percent changes through 2019. The scale of this population, combined with TBRT's demonstrated efficacy and FDA-cleared status, positions the technology to address a substantial unmet need across multiple primary cancer types.

7. With 27.1% of respondents prioritizing lowest risk of side effects and a significant share of free-response answers expressing concern about radioactive implants, the ROADS trial's finding of no difference in serious treatment-related side effects and nearly identical radiation necrosis rates between TBRT and SRT is a critical message. Earlier Cs-131 brachytherapy retrospective data reported 8.4% radiographic radiation necrosis and 11.8% wound complications, providing a longer-term safety context. The combination of Phase 3 safety parity and a decade of Cs-131 real-world data offers a credible evidence base for the side-effect-sensitive patient segment.

Context

Scope: Echo Intelligence fielded [PULSE 5-31-26] Tile-based radiation therapy cuts recurrence in brain metastases with 4 question(s) and 167 responses when this snapshot was captured.

Signal focus: The clearest quantitative signal in this wave comes from questions such as: A new study shows that implanting radioactive tiles during brain tumor surgery dramatically lowers recurrence and more than doubles survival time for patients with brain metastases. How promising does this treatment soun…

Interpretation frame: Results below should be read as directional evidence from this sample, not a census of the whole market.

Findings

Conclusion

What to watch: whether the top finding in this wave shows up again as more responses arrive and whether the gap between groups widens or narrows.

• Dramatic Clinical Results Fail to Translate Into Public Breakthrough Perception: If this pattern proves stable, it should inform the next decision on where to lean in.

• Implant Aversion and Radioactive Material Fear Are the Primary Adoption Barriers: If this pattern proves stable, it should inform the next decision on where to lean in.

Practical takeaway: treat these results as a sharp snapshot—use them to decide what to validate next, not as a final verdict.